Exome Asset Management LLC Kinnate Biopharma Inc. Transaction History

Exome Asset Management LLC

  • $146 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$1.07 - $2.5 $89,717 - $209,620
83,848 New
83,848 $199 Million

Others Institutions Holding KNTE

# of Institutions
2
Shares Held
292K
Call Options Held
0
Put Options Held
0
View Full List

About Kinnate Biopharma Inc.

KNTE Quotes by TradingView
  • Ticker KNTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,145,600
  • Description
  • Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...
More about KNTE
Track This Portfolio

Track Exome Asset Management LLC Portfolio

Follow Exome Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exome Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Exome Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email